Pacific Edge in holding mode as US Medicare decision nears

Pacific Edge in holding mode as US Medicare decision nears
Total laboratory use of Pacific Edge's Cxbladder tests in the US rose in the 2024 financial year but the growth rate slowed in the second half as the company reduced its sales team. (Image: Thinkstock)
Greg Hurrell
Pacific Edge says the 2024 finance year has been one of two halves, as it quickly switched from growth to capital preservation.That sudden change of focus came from a major setback with the possible loss of access to the US Medicare system which has been its largest customer.The company reported a loss of $29.5 million for the March 31 financial year, 9.5% bigger than 2023’s net loss, amid that slowing growth.MedicareThe company said it was prepared for all outcomes as it waited to see whether it would hang on to its Medicare deal, which...

More Markets

Sharesies founders sell down
Markets

Sharesies founders sell down

Global tech investor Rahul Mehta appears on the register for the first time.

Fletcher’s home consenting has tanked: Macquarie
Property

Fletcher’s home consenting has tanked: Macquarie

Building giant’s land sell-off may deepen residential gloom, analysts say.

NZ sharemarket gains as Fletcher hands over NZICC
Markets

NZ sharemarket gains as Fletcher hands over NZICC

Market leader Fisher & Paykel Healthcare was up 25c. 

Graham Skellern 04 Nov 2025